Description: Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Home Page: www.silence-therapeutics.com
72 Hammersmith Road
London,
W14 8TH
United Kingdom
Phone:
44 20 3457 6900
Officers
| Name | Title |
|---|---|
| Mr. Craig A. Tooman M.B.A., MBA | Pres, CEO & Exec. Director |
| Ms. Rhonda L. Hellums | Chief Financial Officer |
| Dr. Giles V. Campion M.D. | Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director |
| Ms. Gem Gokmen Hopkins | Head of IR & Corp. Communications |
| Dr. John Strafford Ph.D. | Sr. VP of Bus. Devel., Alliance Management & New Product Devel. |
| Mr. Jørgen Wittendorff | Sr. VP & Head of Manufacturing |
| Dr. Barbara A. Ruskin J.D., Ph.D. | Sr. VP and Chief Intellectual Property & Innovation Officer |
| Dr. Eric Floyd Ph.D. | Sr. VP of Regulatory Affairs & Quality Assurance |
| Dr. Marie Wikstrom Lindholm Ph.D. | Sr. VP & Head of Molecular Design |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.3581 |
| Price-to-Sales TTM: | 21.6694 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 105 |